Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
23 Cards in this Set
- Front
- Back
|
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) include:
a. b. c. d. e. f. g. h. |
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) include:
a. Zidovudine (AZT) (Retrovir) b. Didanosine (ddI) (Videx) c. Zalcitabine (ddC) (Hivid) d. Stavudine (d4T) (Zerit) e. Lamivudine (3TC) (Epivir) f. Abacavir (Ziagen) g. Tenofovir (Viread) h. Emtricitabine (FTC/ETC?)Emtriva |
|
|
Zidovudine (AZT) Retrovir
method of action: |
Zidovudine (AZT) Retrovir
method of action: Nucleoside analog that inhbits viral replication by BINDING to viral DNA polymerase (REVERSE TRANSCRIPTASE) *this enzyme is involved in the transcription of viral RNA to DNA |
|
|
Zidovudine (AZT) Retrovir
pharmacotherapy: |
Zidovudine (AZT) Retrovir
pharmacotherapy: a. Clinically used in combination with one or more other antiretrovirals in the management of HIV infection b. reduces MATERNAL-FETAL transmission rate by two-thirds (from 26% to 8%) |
|
|
Zidovudine (AZT) Retrovir
safety profile: |
Zidovudine (AZT) Retrovir
safety profile: a. Hematologic: anemia, granulocytopenia b. Headache, myalgias, insomnia |
|
|
Didanosine (ddI) (Videx)
method of action: |
Didanosine (ddI) (Videx)
method of action: similar to zidovudine (AZT) |
|
|
Didanosine (ddI) (Videx)
pharmacokinetics: |
Didanosine (ddI) (Videx)
pharmacokinetics: a. Formulated with buffers to prevent gastric acid degradation b. Food decreases absorption by 50% |
|
|
Didanosine (ddI) (Videx)
pharmacotherapy: |
Didanosine (ddI) (Videx)
pharmacotherapy: Combination therapy in the management of HIV infection |
|
|
Didanosine (ddI) (Videx)
safetey profile: |
Didanosine (ddI) (Videx)
safetey profile: *Most serious adverse reaction is pancreatitis |
|
|
Zalcitabine (ddC) (Hivid)
method of action: |
Zalcitabine (ddC) (Hivid)
method of action: similar to zidovudine (AZT) |
|
|
Zalcitabine (ddC) (Hivid)
pharmacotherapy: |
Zalcitabine (ddC) (Hivid)
pharmacotherapy: Combination therapy in the management of HIV infection |
|
|
Stavudine (d4T) (Zerit)
method of action: |
Stavudine (d4T) (Zerit)
method of action: similar to zidovudine (AZT) |
|
|
Stavudine (d4T) (Zerit)
pharmacotherapy: |
Stavudine (d4T) (Zerit)
pharmacotherapy: Combination therapy in the management of HIV infection |
|
|
Stavudine (d4T) (Zerit)
safety profile: |
Stavudine (d4T) (Zerit)
safety profile: Peripheral neuropathy common (20%) |
|
|
Lamivudine (3TC) (Epivir)
method of action: |
Lamivudine (3TC) (Epivir)
method of action: similar to zidovudine (AZT) |
|
|
Lamivudine (3TC) (Epivir)
pharmacotherapy: |
Lamivudine (3TC) (Epivir)
pharmacotherapy: Combination therapy in the management of HIV infection |
|
|
Lamivudine (3TC) (Epivir)
safety profile: |
Lamivudine (3TC) (Epivir)
safety profile: *Well tolerated |
|
|
Abacavir (Ziagen)
method of action: |
Abacavir (Ziagen)
method of action: similar to zidovudine (AZT) |
|
|
Abacavir (Ziagen)
pharmacotherapy: |
Abacavir (Ziagen)
pharmacotherapy: Combination therapy for the management of HIV infection |
|
|
Abacavir (Ziagen)
safety profile: |
Abacavir (Ziagen)
safety profile: a. General: nausea, vomiting, fatigue, diarrhea b. Serious: 5% incidence of severe hypersensitivity that includes rash, fever, flue-like symptoms, may be life-threatening |
|
|
Tenofovir (Viread)
method of action: |
Tenofovir (Viread)
method of action: similar to zidovudine (AZT) |
|
|
Tenofovir (Viread)
pharmacotherapy: |
Tenofovir (Viread)
pharmacotherapy: Combination therapy for the management of HIV infection |
|
|
Emtricitabine (FTC/ETC?) Emtriva
info: |
Emtricitabine (FTC/ETC?) Emtriva
info: FLOURINATED DERIVATIVE of lamivudine (3TC) (Epivir) |
|
|
NRTI Combination Products includes:
1. 2. 3. 4. |
NRTI Combination Products includes:
1. Combivir 2. Trizivir 3. Truvada 4. Epzicom |
